Like pharmaceutical companies globally - which used to enjoy a preferential exchange rate in Venezuela - Indian producers have been left badly stung by the collapse of the bolivar currency
The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
It is one of 42 drug-making factories in India that the FDA has banned in recent years
The next hearing on Pfizer's plea is slated for March 21
A notice issued by the Indian Health Ministry at the weekend said that a government-appointed committee of experts had found that the banned combinations were "likely to involve risk to human beings, whereas safer alternatives to the said drug are available."
Dinesh Thakur is famous for exposing Ranbaxy safety problems
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
India rejects patent on Pfizer's arthritis drug
Cipla has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients
Few drugs in the market are not approved by the authorities and can be life-threatening.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Sun Pharma open to large acquisitions post Ranbaxy.
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
The new drugs to come under price control include commonly-used antibiotics and painkillers
India's antitrust regulator has approved Sun-Ranbaxy deal, subject to the companies divesting seven products.
Shares in ITC Ltd , India's largest cigarette maker, closed 5.2 per cent lower in a broader Mumbai market that fell 0.8 percent.
Some Indian generic drugmakers are, however, uncertain about the pace of approvals in the near future.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances